Nintedanib

Nov 10, 2017

Results from six-month lung imaging study showed slowing of fibrotic progression in patients with IPF treated with Ofev® versus placebo

Nov 02, 2017

Idiopathic Pulmonary Fibrosis Market - Global Opportunity Analysis and Industry Forecast, 2017-2023

Oct 23, 2017

Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function

Oct 12, 2017

Global Idiopathic Pulmonary Fibrosis Market Expected to Reach $3,569 Million by 2023 - Allied Market Research

Sep 25, 2017

Prometic receives FDA clearance of its IND to initiate pivotal PBI-4050 Phase 2/3 trial in patients with idiopathic pulmonary fibrosis

Sep 11, 2017

Results from the INJOURNEY(TM) trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Jun 05, 2017

Encouraging Phase II survival data for oral nintedanib in malignant pleural mesothelioma presented at ASCO 2017